‍Medicare Deductibles and Copayments

Medicare Deductibles and Copayments refer to the out-of-pocket costs that beneficiaries are responsible for paying under the Medicare program. Here are some key features:

• Deductibles: A deductible is the amount that a beneficiary must pay out-of-pocket before Medicare starts to pay its share of the costs. Medicare has deductibles for both Part A (hospital insurance) and Part B (medical insurance). In 2021, the Part A deductible is $1,484 per benefit period, and the Part B deductible is $203 per year.

• Copayments: A copayment is a fixed amount that a beneficiary pays for a covered service after they have met their deductible. For example, under Part B, beneficiaries typically pay 20% of the Medicare-approved amount for most doctor services and outpatient therapy services.

• Cost-sharing: Cost-sharing refers to the portion of the cost of covered services that beneficiaries are responsible for paying. In addition to deductibles and copayments, cost-sharing may include coinsurance (a percentage of the cost of a service), and other fees.

• Limits on out-of-pocket costs: Medicare also has a limit on the amount that beneficiaries can be required to pay in out-of-pocket costs for covered services in a given year. In 2021, the out-of-pocket limit for Part A and Part B is $7,550.

Overall, Medicare Deductibles and Copayments are designed to ensure that beneficiaries share in the cost of their healthcare services, while also providing some protection against catastrophic expenses.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.